{"protocolSection":{"identificationModule":{"nctId":"NCT03908580","orgStudyIdInfo":{"id":"MT_PRT_ST02"},"organization":{"fullName":"Medy-Tox","class":"INDUSTRY"},"briefTitle":"MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity","officialTitle":"A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb Spasticity"},"statusModule":{"statusVerifiedDate":"2019-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-09-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-10-31","type":"ACTUAL"},"completionDateStruct":{"date":"2015-03-31","type":"ACTUAL"},"studyFirstSubmitDate":"2019-03-26","studyFirstSubmitQcDate":"2019-04-07","studyFirstPostDateStruct":{"date":"2019-04-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-04-07","lastUpdatePostDateStruct":{"date":"2019-04-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Medy-Tox","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is \"A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb Spasticity\"."},"conditionsModule":{"conditions":["Spasticity, Muscle"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":120,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Meditoxin®","type":"EXPERIMENTAL","description":"Botulinum toxin type A was intramuscularly injected up to 360U and up to 4 sites, depending on the muscle size.","interventionNames":["Drug: Meditoxin"]}],"interventions":[{"type":"DRUG","name":"Meditoxin","description":"Meditoxin® (Botulinum toxin type A) was injected up to 360 U.","armGroupLabels":["Meditoxin®"],"otherNames":["Neuronox®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in muscle tone determined by MAS (Modified Ashworth Scale) of wrist flexor","description":"Change in muscle tone determined by MAS (Modified Ashworth Scale: Measures resistance during passive soft-tissue stretching; score 0 to 4, 4 being most difficult passive movement) of wrist flexor in subjects with post stroke upper limb spasticity at week 4 after administration compared to baseline.","timeFrame":"4 weeks"}],"secondaryOutcomes":[{"measure":"Change in muscle tone determined by MAS (Modified Ashworth Scale) of elbow flexor and finger flexor","description":"Change in muscle tone determined by MAS (Modified Ashworth Scale: Measures resistance during passive soft-tissue stretching; score 0 to 4, 4 being most difficult passive movement) of elbow flexor and finger flexor at week 4 and 16 after administration compared to baseline, and at 4 weeks after re-administration compared to the time of re-visit.","timeFrame":"4 weeks, 16 weeks, and 4 weeks after re-visit"},{"measure":"Change in muscle tone determined by MAS (Modified Ashworth Scale) of wrist flexor","description":"Change in muscle tone determined by MAS (Modified Ashworth Scale: Measures resistance during passive soft-tissue stretching; score 0 to 4, 4 being most difficult passive movement) of wrist flexor at week 16 after administration compared to baseline, and at 4 weeks after re-administration compared to the time of re-visit.","timeFrame":"16 weeks, and 4 weeks after re-visit"},{"measure":"The effective rate of wrist flexor, elbow flexor, and finger flexor","description":"The effective rate of wrist flexor, elbow flexor, and finger flexor at week 4 and 16 compared to baseline and at week 4 after re-administration compared to re-visit, defining the muscle with MAS (Modified Ashworth Scale: Measures resistance during passive soft-tissue stretching; score 0 to 4, 4 being most difficult passive movement) score of ≥1 among the wrist flexor, elbow flexor, and finger flexor muscles as responders when the MAS is reduced by 1 score compared to baseline (week 0).","timeFrame":"4 weeks, 16 weeks, and 4 weeks after re-visit"},{"measure":"Change in DAS (Disability Assessment Scale) score","description":"Change in score of goal assessment section in DAS (Disability Assessment Scale: Measures disability associated with upper limb spasticity in patients; score 0 to 3, 3 being the most severe disability) at week 4 and 16 compared to baseline and at week 4 after re-administration compared to re-visit.","timeFrame":"4 weeks, 16 weeks, and 4 weeks after re-visit"},{"measure":"Change in QOL (SF-36v2; Quality of Life) score","description":"Change in score of Short Form 36 ver.2 (SF-36v2; Quality of Life, QOL: a questionnaire with 36 questions regarding general health change affecting patient's quality of life; score from 1 up to 5, from minimum to high impact on quality of life) at week 4 and 16 compared to baseline and at week 4 after re-administration compared to re-visit.","timeFrame":"4 weeks, 16 weeks, and 4 weeks after re-visit"},{"measure":"Subject's or caregiver's global assessment","description":"Subject's or caregiver's global assessment (rating from -3 to +3 on the overall treatment effect, with +3 being very satisfied with treatment) at week 4 and 16 compared to baseline and at week 4 after re-administration compared to re-visit.","timeFrame":"4 weeks, 16 weeks, and 4 weeks after re-visit"},{"measure":"Number of participants with Adverse Events (AEs) to assess safety of investigational product.","description":"Safety of IP assessed by the number of partiicipants with adverse events determined by MedDra ver 16.0 from enrollment to the end of study.","timeFrame":"Through study completion, an average of 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female over 20 years.\n2. Subjects that was diagnosed with stroke at least 1 month before participating in the clinical trial.\n3. Subjects with MAS score of ≥2 for local muscle spasticity of wrist flexor.\n\nExclusion Criteria:\n\n1. Subjects with generalized neuromuscular junction disorder (ex: myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, etc.).\n2. Subjects with fixed joint, muscle contracture, or atrophy in the treatment area.\n3. Subjects with botulinum toxin treatment within 3 months before administration of the investigational product.\n4. Known immunization or hypersensitivity to any botulinum toxin preparations.\n5. Subjects who have recieved the following treatments within 4 weeks from screening: Muscle relaxants, Benzodiazepines, Aminoglycosides, Other antibiotics, Anticholinergics","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000019274","term":"Botulinum Toxins, Type A"}],"ancestors":[{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Vascularization","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}